Form4insider filings, from the source

SEC Form 4 · accession 0001209191-16-095647

Orexigen Therapeutics, Inc. · OREXQ

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Preston Klassen
Officer — EVP, Global Development
Period of report
Feb 2, 2016
Accepted (ET)
Feb 4, 2016 · 12:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382911

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockMay 30, 2015A1,860$4.17A5,990D
Common StockNov 30, 2015A4,170$2.03A10,160D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F3,F2$1.78Feb 2, 2016A190,000A—Feb 1, 2026Common Stock190,000190,000D
Performance Stock UnitsF4—Feb 2, 2016A350,000A—Feb 1, 2021Common Stock350,000350,000D

Explanation of responses